Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaust Limited ( (AU:NUZ) ) just unveiled an update.
Neurizon Therapeutics has presented new preclinical data on its lead candidate NUZ-001 at the ASENT 2026 meeting, strengthening mechanistic support for its use in Huntington’s disease models. The data show that both NUZ-001 and its active metabolite, NUZ-001 Sulfone, are taken up in vivo and exhibit biological activity, including disease-dependent restoration of BDNF and enhancement of autophagic protein clearance pathways.
The findings suggest a dual mechanism in Huntington’s disease involving improved proteostasis and restoration of neurotrophic support under stress conditions. While NUZ-001 is currently in clinical evaluation for ALS in the HEALEY ALS Platform Trial, the expanding preclinical evidence in Huntington’s disease underscores its potential to broaden Neurizon’s pipeline and strategic positioning in neurodegenerative therapeutics.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead investigational drug, NUZ-001, is being developed primarily for amyotrophic lateral sclerosis while the company explores broader applications across disorders marked by impaired protein homeostasis.
Average Trading Volume: 578,603
Technical Sentiment Signal: Sell
Current Market Cap: A$61.48M
See more data about NUZ stock on TipRanks’ Stock Analysis page.